Ventilator Induced Diaphragm Dysfunction in Pediatric Critically Ill Patients (VIDD) (VIDD)
Ventilator Induced Diaphragm Dysfunction in Pediatric Critically Ill Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Physician will perform US diaphragm measurements within 36 hours of initiation of MV. Measurements will be repeated daily for the duration of MV for the first week, then every 48 hours and 24 hours after the extubation.
Exposure to and duration of continuous NMBA infusion during the course of MV and use of CS will be recorded.
Ventilator logs and arterial gas analysis will be checked at the time of each US measurement to ascertain ventilator settings and SBF for the 24 hours preceding each US measurement.
Extubation success will be defined as no requirement for reintubation within 48 hours following extubation. The use of NIV immediately after extubation will be decided by the physician in charge according to the patient clinical history (presence of withdrawal syndrome, ect) and NOT according to DTF measurement.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients younger than 18 years old
- expected clinical requiring of invasive MV for more than 36 hours
Exclusion Criteria:
- neonates
- subjects with preexisting diagnoses of neuromuscular weakness
- diaphragm paresis
- chronic respiratory failure with ongoing requirement for invasive MV, or continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) or with likely death within 48 hours.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
measurement of occurrence rate of ventilator induced diaphragm disfunction in pediatric patient
Time Frame: through study completion an average of 100 days
|
the assessment of the actual occurrence rate of VIDD in a population of PICU patients undergoing MV for acute respiratory failure of various etiology
|
through study completion an average of 100 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
evaluation clinical impact of ventilator induced diaphragm disfunction in pediatric patient
Time Frame: through study completion an average of 100 days
|
evaluation of the impact of VIDD and clinical outcomes of our patients in terms of Mechanical Ventilation free days
|
through study completion an average of 100 days
|
|
evaluation of two different diaphragmatic thickening fraction formula (DTF)
Time Frame: through study completion an average of 100 days
|
evaluate the feasibility and clinical applicability of our formula for the calculation of DTF (mTdi-insp - mTdi-exp)/mTdi-med x 100, comparing it to the standard one (Tdi-insp - Tdi-exp)/Tdi-exp x 100.
|
through study completion an average of 100 days
|
|
evaluation clinical impact of ventilator induced diaphragm disfunction in pediatric patient
Time Frame: through study completion an average of 100 days
|
evaluation of the impact of VIDD and clinical outcomes of our patients, in terms of MV free days, PICU length of stay (LOS) - days
|
through study completion an average of 100 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Levine S, Nguyen T, Taylor N, Friscia ME, Budak MT, Rothenberg P, Zhu J, Sachdeva R, Sonnad S, Kaiser LR, Rubinstein NA, Powers SK, Shrager JB. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med. 2008 Mar 27;358(13):1327-35. doi: 10.1056/NEJMoa070447.
- Demoule A, Jung B, Prodanovic H, Molinari N, Chanques G, Coirault C, Matecki S, Duguet A, Similowski T, Jaber S. Diaphragm dysfunction on admission to the intensive care unit. Prevalence, risk factors, and prognostic impact-a prospective study. Am J Respir Crit Care Med. 2013 Jul 15;188(2):213-9. doi: 10.1164/rccm.201209-1668OC.
- Kim WY, Suh HJ, Hong SB, Koh Y, Lim CM. Diaphragm dysfunction assessed by ultrasonography: influence on weaning from mechanical ventilation. Crit Care Med. 2011 Dec;39(12):2627-30. doi: 10.1097/CCM.0b013e3182266408.
- Francis CA, Hoffer JA, Reynolds S. Ultrasonographic Evaluation of Diaphragm Thickness During Mechanical Ventilation in Intensive Care Patients. Am J Crit Care. 2016 Jan;25(1):e1-8. doi: 10.4037/ajcc2016563.
- Glau CL, Conlon TW, Himebauch AS, Yehya N, Weiss SL, Berg RA, Nishisaki A. Progressive Diaphragm Atrophy in Pediatric Acute Respiratory Failure. Pediatr Crit Care Med. 2018 May;19(5):406-411. doi: 10.1097/PCC.0000000000001485.
- Goligher EC, Dres M, Fan E, Rubenfeld GD, Scales DC, Herridge MS, Vorona S, Sklar MC, Rittayamai N, Lanys A, Murray A, Brace D, Urrea C, Reid WD, Tomlinson G, Slutsky AS, Kavanagh BP, Brochard LJ, Ferguson ND. Mechanical Ventilation-induced Diaphragm Atrophy Strongly Impacts Clinical Outcomes. Am J Respir Crit Care Med. 2018 Jan 15;197(2):204-213. doi: 10.1164/rccm.201703-0536OC.
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 001 (Buy Pharma Ecza Deposu San. Tic. Ltd.)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Failure
-
NCT07334457RecruitingRespiratory Failure | Cardiac Failure
-
NCT04183660RecruitingRespiratory Failure | Cardiac Failure | Cardio-Respiratory Failure | Imminent Cardiorespiratory or Respiratory Failure
-
NCT02107183CompletedWeaning Failure | Acute Respiratory Failure
-
NCT04079829UnknownShock | Shock, Septic | Respiratory Failure | Respiratory Distress Syndrome | Shock, Cardiogenic | Acute Cardiac Failure | Acute Respiratory Failure | Acute Kidney Failure | Multi Organ Failure | Respiratory Arrest
-
NCT00977002UnknownExtubation Failure | Acute Respiratory Failure Post Extubation
-
NCT03872167CompletedHypercapnic Respiratory Failure | Hypoxemic Respiratory Failure
-
NCT06694870CompletedHypercapnic Respiratory Failure | Type 2 Respiratory Failure
-
NCT06007495RecruitingAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
NCT06204276CompletedAcute Hypoxemic Respiratory Failure | Acute Hypercapnic Respiratory Failure
-
NCT05082324Not yet recruiting
Clinical Trials on ultrasound asessment
-
NCT06568822CompletedPhysical Activity | Medication Adherence | Older Adults | Life Satisfaction
-
NCT05838807CompletedCarpal Tunnel Syndrome | Median Neuropathy, Carpal Tunnel
-
NCT02054247CompletedCarpal Tunnel Syndrome
-
NCT00653874CompletedHyperbilirubinemia
-
NCT05005936Withdrawn
-
NCT01681901Withdrawn
-
NCT03195556RecruitingPeripheral Arterial Disease
-
NCT02638649CompletedPneumonia | Pulmonary Edema | Dyspnea
-
NCT06844331Enrolling by invitationThoracic Ultrasound | Fibrosing Interstitial Lung Diseases